Piperacillin-Tazobactam versus other antibacterial agents for treatment of bloodstream infections due to AmpC β-Lactamase-producing enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 6, 2017, Pages

  Cheng, Lucy ^a   Nelson, Brian C ^b   Mehta, Monica ^b   Seval, Nikhil ^a   Park, Sarah ^a   Giddins, Marla J ^a   Shi, Qiuhu ^c   Whittier, Susan ^a   Gomez Simmonds, Angela ^a   Uhlemann, Anne Catrin ^a  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Ampc beta lactamases; Bacteremia; Piperacillin Tazobactam

Indexed keywords

BETA LACTAMASE AMPC; CEFEPIME; CEFOXITIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ADULT; AGED; ALLELE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOOD CULTURE; BLOODSTREAM INFECTION; CASE CONTROL STUDY; CITROBACTER; CITROBACTER BRAAKII; CITROBACTER FREUNDII; CITROBACTER KOSERI; CITROBACTER YOUNGAE; CLINICAL OUTCOME; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; ENTEROBACTER; ENTEROBACTER AEROGENES; ENTEROBACTER ASBURIAE; ENTEROBACTER CANCEROGENUS; ENTEROBACTER CLOACAE; FEMALE; FOLLOW UP; GENE SEQUENCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; MORTALITY; OUTCOME ASSESSMENT; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SEPTIC SHOCK; SERRATIA LIQUEFACIENS; SERRATIA MARCESCENS; SINGLE NUCLEOTIDE POLYMORPHISM; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ENTEROBACTERIACEAE; ENZYMOLOGY; GENETICS; GENOTYPE; METABOLISM; MICROBIOLOGY; PHENOTYPE;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CASE-CONTROL STUDIES; ENTEROBACTERIACEAE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PHENOTYPE; PIPERACILLIN; SERRATIA MARCESCENS;

EID: 85019688988     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00276-17     Document Type: Article

References (24)

1. Livermore DM. 1995. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557-584.
2. CDC. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/drugresistance/threat-report-2013/.
3. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. https://doi.org/10.1086/595011.
4. Nordmann P, Poirel L. 2014. The difficult-To-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 20:821- 830. https://doi.org/10.1111/1469-0691.12719.
5. Jacoby GA. 2009. AmpC beta-lactamases. Clin Microbiol Rev 22:161-182. https://doi.org/10.1128/CMR.00036-08.
6. Harris PN. 2015. Clinical management of infections caused by Enterobacteriaceae that express extended-spectrum beta-lactamase and AmpC enzymes. Semin Respir Crit Care Med 36:56 -73. https://doi.org/10.1055/s-0034-1398387.
7. Bennett PM, Chopra I. 1993. Molecular basis of beta-lactamase induction in bacteria. Antimicrob Agents Chemother 37:153-158. https://doi.org/10.1128/AAC.37.2.153.
8. Kaneko K, Okamoto R, Nakano R, Kawakami S, Inoue M. 2005. Gene mutations responsible for overexpression of AmpC beta-lactamase in some clinical isolates of Enterobacter cloacae. J Clin Microbiol 43: 2955-2958. https://doi.org/10.1128/JCM.43.6.2955-2958.2005.
9. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL. 1991. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115:585-590. https://doi.org/10.7326/0003-4819-115-8-585.
10. Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, Cosgrove SE, Carroll KC. 2013. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis 57: 781-788. https://doi.org/10.1093/cid/cit395.
11. Siedner MJ, Galar A, Guzman-Suarez BB, Kubiak DW, Baghdady N, Ferraro MJ, Hooper DC, O'Brien TF, Marty FM. 2014. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis 58:1554 -1563. https://doi.org/10.1093/cid/ciu182.
12. Harris PN, Alder L, Paterson DL. 2015. Antimicrobial susceptibility reporting and treatment selection for AmpC-producing Enterobacteriaceae: What do microbiologists and infectious disease practitioners actually practice? Pathology 47:386 -388. https://doi.org/10.1097/PAT.0000000000000255.
13. Harris PN, Peri AM, Pelecanos AM, Hughes CM, Paterson DL, Ferguson JK. 2017. Risk factors for relapse or persistence of bacteraemia caused by Enterobacter spp.: A case-control study. Antimicrob Resist Infect Control 6:14. https://doi.org/10.1186/s13756-017-0177-0.
14. Schwaber MJ, Graham CS, Sands BE, Gold HS, Carmeli Y. 2003. Treatment with a broad-spectrum cephalosporin versus piperacillin-Tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother 47:1882-1886. https://doi.org/10.1128/AAC.47.6.1882-1886.2003.
15. Perez-Perez FJ, Hanson ND. 2002. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 40:2153-2162. https://doi.org/10.1128/JCM.40.6.2153-2162.2002.
16. Austin PC. 2011. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46:399-424. https://doi.org/10.1080/00273171.2011.568786.
17. Marcos M, Inurrieta A, Soriano A, Martinez JA, Almela M, Marco F, Mensa J. 2008. Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia. J Antimicrob Chemother 62:397- 403. https://doi.org/10.1093/jac/dkn155.
18. Harris PN, Wei JY, Shen AW, Abdile AA, Paynter S, Huxley RR, Pandeya N, Doi Y, Huh K, O'Neal CS, Talbot TR, Paterson DL. 2016. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: A systematic review with meta-Analysis. J Antimicrob Chemother 71:296 -306. https://doi.org/10.1093/jac/dkv346.
19. Moy S, Sharma R. 2016. Treatment outcomes in infections caused by "SPICE" (Serratia, Pseudomonas, indole-positive Proteus, Citrobacter, and Enterobacter) organisms: carbapenem versus noncarbapenem regimens. Clin Ther 39:170 -176. https://doi.org/10.1016/j.clinthera.2016.11.025.
20. Moradigaravand D, Boinett CJ, Martin V, Peacock SJ, Parkhill J. 2016. Recent independent emergence of multiple multidrug-resistant Serratia marcescens clones within the United Kingdom and Ireland. Genome Res 26:1101-1109. https://doi.org/10.1101/gr.205245.116.
21. CLSI. 2015. Performance standards for antimicrobial susceptibility testing. Twenty-fifth informational supplement, document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. https://doi.org/10.1016/0021-9681(87)90171-8.
23. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL. 2004. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extendedspectrum beta-lactamases. Clin Infect Dis 39:31-37. https://doi.org/10.1086/420816.
24. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest 101:1644 -1655.